Elevation Oncology Announces Clinical Cancer Research Publication Highlighting the Specific Inhibition of HER3 by Seribantumab in Preclinical NRG1 Fusion Models
- Results show seribantumab efficiently inhibited HER3 and the entire ERBB family signaling pathway and established a biologically effective dose range for tumors driven by an NRG1 fusion -
- Seribantumab is currently being evaluated in the tumor-agnostic Phase 2 CRESTONE trial for patients with any solid tumor harboring an NRG1 fusion -
News provided by
Share this article
Share this article
NEW YORK, April 6, 2021 /PRNewswire/ Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the publication in